Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be at least 18 years of age;~2. Give written informed consent;~3. Be in good general health as determined by your doctor;~4. Have a diagnosis of unilateral or bilateral glaucoma or ocular hypertension;~5. If you are a female of child bearing potential, you must be willing to practice effective contraception for the duration of the study (i.e., abstinence, spermicide, condoms, or birth control pills);~6. Understand the study instructions, and be able to follow the study instructions; and~7. Be likely to complete the entire study period (12 weeks), including all regularly scheduled study visits.~Exclusion Criteria:~1. Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation;~2. Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results; and~3. Concurrent participation or prior participation in any investigational drug or device study within the last 30 days prior to the Screening Visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution
- 2 (Type: ACTIVE_COMPARATOR): Latanoprost 0.005% ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).